IL6 and congenital rubella syndrome: As indicated by the FDA (33, 34), the inpatient pharmacy will need to stock at least two doses of tocilizumab for each patient before CAR-T cell administration and ordering protocols and order sets will need to be developed to assure timely administration of both anti-IL-6 therapy as well as corticosteroids and supportive medications as needed for CRS (28).